- MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 1, first line PID 1333 V2.3 (2026-03-11)
V2.3:
Protocol name changed, name of the study added
V2.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V2.1:
Protocol name changed
V2.0:
Cato test done
Separation of cycle 1+2 into cycle 1 and cycle 2 (see PID 1437)
Simplification and adjustment of dexamethasone therapy on the days of daratumumab therapy
Addition of Montelukast on day 1
V1.0:
Cato test done.
V0.1:
Duration according to summary of product characteristics
- MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 3-6, first line PID 1337 V2.3 (2026-03-11)
V2.3:
Protocol name changed, name of the study added
V2.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V2.1:
Protocol name changed
V2.0:
Cato test done
Simplification and adjustment of dexamethasone therapy on the days of daratumumab therapy
V1.0:
Cato test done.
V0.1:
Duration according to the summary of product characteristics
- MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 7+, first line PID 1338 V2.3 (2026-03-11)
V2.3:
Protocol name changed, name of the study added
V2.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V2.1:
Protocol name changed
V2.0:
Cato test done
Simplification and adjustment of dexamethasone therapy on the days of daratumumab therapy
V1.0:
Cato test done.
V0.1:
Duration according to the summary of product characteristics
- MAIA - Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone (20/20), multiple myeloma, cycle 1, first line PID 1436 V1.3 (2026-03-11)
1.3:
Protocol name changed, name of the study added
V1.2:
Insertion of hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Protocol name changed
V1.0:
Cato test done
Runtimes according to the summary of product characteristics
Addition of Montelukast on day 1
- MAIA - Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 2, first line PID 1437 V1.3 (2026-03-11)
V1.3:
Protocol name changed, name of the study added
V1.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Protocol name changed
V1.0:
Cato test done
Runtimes according to the summary of product characteristics
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab (8/8/16) / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1 PID 1482 V1.3 (2026-03-11)
V1.3:
Protocol title changed, study name added
V1.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Supportive therapy adapted
Cato test done
V1.0:
Cato test done
Dosing and running times according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 40, multiple myeloma, cycle 2 PID 1483 V1.3 (2026-03-11)
V1.3:
Protocol title changed, study name added
V1.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Supportive therapy adapted
Cato test done
V1.0:
Cato test done
Dosing and running times according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone (40/20), multiple myeloma, cycle 3-4 PID 1484 V1.2 (2026-03-11)
V1.2:
Protocol title changed, study name added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Supportive therapy adapted
Cato test done
V1.0:
Cato test done
Dosing and running times according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation PID 1485 V1.3 (2026-03-11)
V1.3:
Protocol title changed, study name added
V1.2:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012.
V1.1:
Supportive therapy adapted
Cato test done
V1.0:
Cato test done
Dosing and running times according to primary literature.
- CASSIOPEIA - Daratumumab 16, maintenance after Bortezomib 1.3 / Daratumumab 16 / Dexamethasone 20 / Thalidomide 100, Multiple Myeloma PID 1486 V1.1 (2026-03-11)
V1.1:
Protocol title changed, study name added
V1.0:
Cato test done
Dosing and running times according to primary literature.
- MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 1-2, first line PID 1625 V1.2 (2026-03-11)
V1.2:
Protocol name changed, name of the study added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Correction of allergy prophylaxis
V1.0:
Cato test done
V0.1:
Application according to summary of product characteristics
- MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 3-6, first line PID 1626 V1.2 (2026-03-11)
V1.2:
Protocol name changed, name of the study added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Correction of allergy prophylaxis
V1.0:
Cato test done
V0.1:
Application according to summary of product characteristics
- MAIA - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), multiple myeloma, cycle 7+, first line PID 1627 V1.2 (2026-03-11)
V1.2:
Protocol name changed, name of the study added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Correction of allergy prophylaxis
V1.0:
Cato test done
V0.1:
Running times according to summary of product characteristics
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 40, multiple myeloma, cycle 1-2 PID 1628 V1.2 (2026-03-11)
V1.2:
Protocol title changed, study name added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Adaptation of allergy prophylaxis to standard
V1.0:
Cato test done
V0.1:
Dosing according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone (40/20), multiple myeloma, cycle 3-4 PID 1629 V1.2 (2026-03-11)
V1.2:
Protocol title changed, study name added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Adaptation of allergy prophylaxis to standard
V1.0:
Cato test done
V0.1:
Dosing according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation PID 1630 V1.2 (2026-03-11)
V1.2:
Protocol title changed, study name added
V1.1:
Cato test done.
Insertion of the hematopoietic growth factors module according to Palumbo et al. 2012. Adaptation of allergy prophylaxis to standard
V1.0:
Cato test done
V0.1:
Dosing according to primary literature.
- CASSIOPEIA - Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone 20 / Thalidomide 100 - Daratumumab 1800 Maintenance, Multiple Myeloma PID 1635 V1.2 (2026-03-11)
V1.2:
Protocol title changed, study name added
V1.1:
Correction allergy prophylaxis and title
V1.0:
Cato test done
Dosing according to primary literature and summary of product characteristics.
- LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-2 PID 1941 V1.1 (2026-03-11)
V1.1:
Protocol title changed. Study name added.
V1.0:
Cato test done
V0.1:
Dosing and running times according to primary literature. Dosing of Dexamethasone according to summary of product characteristics.
- LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 3-6 PID 1942 V1.1 (2026-03-11)
V1.1:
Protocol title changed. Study name added.
V1.0:
Cato test done
V0.1:
Dosing and running times according to primary literature. Dosing of Dexamethasone according to summary of product characteristics.
- LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 7-8 PID 1943 V1.1 (2026-03-11)
V1.1:
Protocol title changed. Study name added.
V1.0:
Cato test done
V0.1:
Dosing and running times according to primary literature. Dosing of Dexamethasone according to summary of product characteristics.
- LYRA - Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20) - Daratumumab 1800 / Dexamethasone 12, Multiple Myeloma, maintenance PID 1944 V1.1 (2026-03-11)
V1.1:
Protocol title changed. Study name added.
V1.0:
Cato test done
V0.1:
Dosing and running times according to primary literature. Dosing of Dexamethasone according to summary of product characteristics.
